Study Summary
This is a open-label, single center to determine the efficacy and safety of IM96 CAR-T cells in Patients With Advanced Digestive System Neoplasms
Interested in this trial?
Submit an InquiryInterventions
IM96 CAR-T cellsDRUG
treatment with anti-GUCY2C chimeric antigen receptor T-cell infusion
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Beijing Cancer Hospital | Beijing | Beijing Municipality | China |